Terrance Mcguire Sells 83,817 Shares of Invivyd, Inc. (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) Director Terrance Mcguire sold 83,817 shares of the company's stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $0.54, for a total value of $45,261.18. Following the completion of the transaction, the director now directly owns 3,340,520 shares of the company's stock, valued at approximately $1,803,880.80. This trade represents a 2.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Terrance Mcguire also recently made the following trade(s):

• On Monday, December 23rd, Terrance Mcguire sold 75,776 shares of Invivyd stock. The shares were sold at an average price of $0.45, for a total transaction of $34,099.20.
• On Friday, December 20th, Terrance Mcguire sold 119,805 shares of Invivyd stock. The stock was sold at an average price of $0.42, for a total value of $50,318.10.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total value of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total transaction of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Price Performance

IVVD stock traded up $0.02 during trading on Thursday, hitting $0.53. 870,708 shares of the company traded hands, compared to its average volume of 667,876. Invivyd, Inc. has a 1 year low of $0.40 and a 1 year high of $5.20. The company has a market cap of $63.44 million, a PE ratio of -0.27 and a beta of 0.53. The stock's 50-day simple moving average is $0.74 and its 200 day simple moving average is $0.99.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Morgan Stanley dropped their price target on shares of Invivyd from $9.50 to $3.55 and set an "overweight" rating for the company in a research note on Wednesday, November 20th. HC Wainwright dropped their target price on Invivyd from $15.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, November 20th. D. Boral Capital reaffirmed a "buy" rating and set a $9.00 target price on shares of Invivyd in a research note on Thursday, November 21st. Finally, EF Hutton Acquisition Co. I raised Invivyd to a "strong-buy" rating in a research note on Wednesday, October 30th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $7.89.

Institutional Trading of Invivyd

Several institutional investors have recently modified their holdings of the stock. Duquesne Family Office LLC purchased a new position in shares of Invivyd in the second quarter valued at approximately $629,000. Acadian Asset Management LLC lifted its holdings in Invivyd by 232.0% in the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company's stock valued at $745,000 after purchasing an additional 474,301 shares in the last quarter. Cornercap Investment Counsel Inc. acquired a new stake in Invivyd during the 2nd quarter worth $86,000. Cubist Systematic Strategies LLC raised its position in shares of Invivyd by 66.1% in the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company's stock valued at $148,000 after buying an additional 53,499 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of Invivyd by 198.6% in the second quarter. SG Americas Securities LLC now owns 37,893 shares of the company's stock worth $42,000 after buying an additional 25,201 shares in the last quarter. Institutional investors and hedge funds own 70.36% of the company's stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.